Tepezza net sales

The government mandate to prioritize vaccine production has led to a shortage of Horizon Therapeutics’ top-selling product. The shortage deprives Horizon of sales, and patients can’t get the only approved treatment for thyroid eye disease, which causes bulging eyes and vision problems.

2021 data is a Wall Street estimate. Tepezza was approved by the FDA on Jan. 21, 2020.
Chart: SEC filings Source: SEC filings Get the data